Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of LY3015014 in primary hypercholesterolemia
2013-000622-55Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing LY3015014 arm with Placebo arm (2 arms). Primary endpoints: Primary endpoint: mean percentage change in LDL-C (beta quantification) from baseline to week 16 and Primary endpoint: absolute change in LDL-C (beta quantification) from baseline to week 16. Started May 2013; status: completed.
02
Drugs
frovocimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2013-000622-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000622-55.